Thierry Le Tourneau is an expert in Cardiology at Centre Hospitalier Universitaire de Nantes (France). Thierry Le Tourneau has authored 246 publications, the most recent in 2026, and is an investigator in 17 clinical trials, 4 of them ongoing. SLR score: 792 (community average: 125). How the SLR is computed.

LeadR Profile

792 ScienceLeadR Reputation 792
Network Map

Cardiology

Subspecialties: Public Health - Thoracic And Cardiovascular Surgery - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

Thierry Le Tourneau, M.D., Ph.D.

Date of Birth : May 25, 1966; Citizenship: French

Graduaded in Cardiology, and Vascular Medicine, Professor of Physiology


Curriculum

Thierry Le Tourneau obtained his MD and became qualified specialist in Cardiology in 1994, qualified in Vascular Medicine in 1998, and obtained a PhD degree in 2002. In 2007-2008 he was postdoctoral fellow at Mayo Clinic, MN (Valve Heart Clinic and Echocardiography Laboratory) where he worked on clinical and echocardiographic aspects of heart valve diseases under the supervision of Pr Enriquez-Sarano. Back from the USA, he joined the Inserm U1087 – institut du thorax as a Professor of Physiology in the cardiovascular field to develop clinical and experimental echocardiography, and to promote translational research in heart valve diseases from clinical to physiopathological and genetic approaches. He participated to the Transatlantic Leducq Mitral network, and to the FP7 Translink European network (SVD of heart valve bioprostheses). He has 200 international peer-reviewed publications including publications in major medical journals, > 7500 citations, H index 46 in 2025. Head of Physiology Laboratory and Echocardiography Departments, University Hospital of Nantes, France.


Research


200 peer review papers; 7951 citations; h-index: 47

Th Le Tourneau organized translational research in valve heart disease in the University of Lille to understand the pathophysiology of valve lesions and the interaction with hemostasis factor (von Willebrand Factor, Tissue factor). In 2003 the team identified the strong impact of shear stress on primary hemostasis in aortic stenosis (Vincentelli et al, N Engl J med, 2003; IF 38.5; 843 citations). This work led to the identification of a new pathophysiological concept in high shear stress cardiac lesions, proven also in the obstructive form of hypertrophic cardiomyopathy (Le Tourneau et al, Circulation 2008; IF 14.8; 67 citations). In parallel, he developed clinical research to improve the management of patients with severe valve diseases, influencing international guidelines on heart valve diseases (Le Tourneau et al, Heart 2010; IF 4.2, 128 citations; Le Tourneau et al, JACC 2010; IF 12.5; 217 citations).


He joined the “Institut du Thorax” - Inserm U1087 in 2009 to address the genetics and physiopathology of valve diseases with JJ Schott, V Probst and H le Marec. He participated to the Mitral Leducq network and set-up a large prospective cohort of mitral valve prolapse which led to several publications regarding the phenotype of MVP (Eur Heart J 2018, 68 citations) including arrhythmic MVP (Circulation 2021, 120 citations), and genetics. He participated to the Translink European project on bioprosthetic immune response under the 7th framework program (Nature Medicine 2022, IF 87.2, 62 citations), and was involved in the enrollment of a large prospective cohort of patients with bioprostheses.


Management


-2005: Associate director, Echocardiography department and Valve Heart Disease department, University Cardiology Hospital of Lille, France

-2009: Head of Cardiovascular Physiology Department, University Hospital of Nantes, France, and Head of Echo Lab, University Hospital of Nantes

-2023: Head of Physiology Department, University Hospital of Nantes, France

Organizations

Career arc: 1994 - 2026

Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Frailty and Five-Year Mortality After TAVR in Patients Aged 75 Years and Older.
PMID 42587247 — mortality, aged, transcatheter aortic valve replacement, frailty, geriatrics
J Am Geriatr Soc20260
Cinefluoroscopy: the Tom Thumb or the David of cardiovascular imaging for mechanical heart valves?
PMID 42483985 — heart, cardiology, heart valves
Acta Cardiol20261
Macrophage recruitment is a hallmark of non-syndromic myxomatous mitral valve disease.
PMID 42334384 — cells, genes, mitral valve, macrophages
Cardiovasc Res20260
Contemporary Surgical Outcomes and Repair Rates in Degenerative Mitral Regurgitation: Real World Insights from the International MITRACURE Registry.
PMID 42092496 — registries, mortality, thoracic surgery, early intervention, educational, cardiovascular diseases, hospital mortality, mitral valve insufficiency
J Thorac Cardiovasc Surg20260
Extent and progression of cardiac damage in patients with primary mitral regurgitation undergoing surgical repair.
PMID 41967857 — mortality, thoracic surgery, mitral valve prolapse, mitral valve insufficiency, mitral valve annuloplasty
Eur J Cardiothorac Surg20260

Clinical Studies 17

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

N/A 11
Phase 3 2
Phase 1 1
Phase 1/Phase 2 1
Phase 2 1
Phase 4 1

By status:

Completed 8
Recruiting 3
Unknown 3
Terminated 2
Enrolling by invitation 1

By type:

Interventional 10
Observational 7

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 2
multicentric5to9 2
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Rifampin free regimen versus rifampin containing regimen in the treatment of staphylococcal prosthetic valve endocarditis a multicenter randomized controlled non inferiority study (RIFREE)
2024-518018-22-00 — endocarditis, therapeutics, rifampin
Phase 3Recruiting2026
Rifampin free Regimen Versus Rifampin containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis
NCT07345325 — staphylococcal infections, staphylococcus, endocarditis, physicians, staphylococcus aureus, therapeutics, rifampin, infections
Phase 3Recruiting2026
Echocardiography in Nursing Home
NCT06445231 — heart valve diseases, heart diseases, heart failure, heart, nursing, home nursing, nursing homes, physicians, echocardiography, cardiologists, heart valves
N/ARecruiting2024
Outcome of Patients With Severe Functional TR According to Medical Transcatheter or Surgical Treatment
NCT05825898 — mortality, surgical procedures, operative, hospital mortality, tricuspid valve, therapeutics, tricuspid valve insufficiency
N/AEnrolling by invitation2022

LeadR Networks

Main global connection map